skip to content


Issue No. 41 | October 3, 2008

News and Features

CDC Publishes Estimated Prevalence of HIV Infection in the United States

"CDC's analysis reveals that more than a million people - an estimated 1,106,400 adults and adolescents - were living with HIV infection in the United States at the end of 2006. This analysis also reveals some important news about progress in our nation's fight against HIV/AIDS."

Read the full report here and a Q&A on the new estimate.

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Releases 2006 Disease Profile Report

"This report includes a review of HIV/AIDS, viral hepatitis, STD, and TB surveillance data, and a special focus section on African-American men to illustrate how these diseases and the factors that influence them may overlap and result in excess disease burden among certain populations."

Read the full report here. [PDF]

FDA Approves New Pediatric Label Changes for Didanosine (Videx EC)

"On September 29, 2008, FDA approved a pediatric efficacy supplement for Videx EC (didanosine) Delayed-Release Capsules, expanding the indication to include children weighing at least 20 kg."

The updated label will be available from the FDA soon. More information is available:

FDA Approves Alternative Dosing Regimen for Atazanavir (Reyataz) in Treatment-Naive Patients

"On September 30, 2008, FDA approved an alternative dosing regimen for Reyataz (atazanavir) for HIV-1 infected treatment-naive patients who can take ritonavir. The recommended dosage is Reyataz 300 mg with ritonavir 100 mg once daily for treatment-naive patients."

The updated label will be available from the FDA soon. More information is available:

  • FDA: Atazanavir Label and Approval History
  • AIDSinfo: Atazanavir Drug Fact Sheet
  • AIDSinfo: Adult Treatment Guidelines

Emergence of HIV/AIDS Traced to Colonial-Era Africa

"New research suggests that AIDS among humans occurred at least three decades earlier than previously thought."

Read the full story.

Study: Once-Daily Boosted Darunavir Similar to Twice-Daily for Some Patients

"Treatment-experienced, HIV-infected patients with no baseline darunavir RAMs achieved similar high responses with darunavir/r 800/100 mg once daily and 600/100 mg twice daily."

More information is available:

  • PubMed: Study Abstract
  • AIDSinfo: Darunavir Drug Fact Sheet

Study: Ezetimibe Reduces LDL Cholesterol in Patients Receiving HAART

"Ezetimibe was safe and effective in reducing low-density lipoprotein cholesterol and is an option for patients who cannot tolerate treatment with a statin."

For more information, read the study abstract.

Study: Anti-Obesity Treatments May Fight Viral Infections

"Drugs used to treat obesity may be effective against a wide range of viral infections such as the flu, hepatitis, and even HIV ... ."

For more information, read the full story.

Study: Three Million Injection Drug Users Could Be HIV-Positive

"As the number of countries reporting intravenous drug use has increased over the last decade, a new study suggests that as many as 3 million of these addicts may be HIV-positive."

For more information, read the full story.